Loading clinical trials...
Loading clinical trials...
A Study to Evaluate the Safety and Efficacy of Donor-derived CAR-T Cells in the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions
Interventions
CAR-T cells
Locations
1
China
Peking University People's Hospital (PKUPH)
Beijing, China
Start Date
March 1, 2021
Primary Completion Date
June 1, 2023
Completion Date
December 1, 2023
Last Updated
February 23, 2021
NCT06973668
NCT05735717
NCT06834282
NCT05768932
NCT07486713
NCT06859424
Xiaojun Huang, MD
CONTACT
Lead Sponsor
Beijing Immunochina Medical Science & Technology Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions